9,721,067OCR.pdf (1.64 MB)
Accelerated progression relapse test
standard
posted on 2017-11-30, 00:00 authored by Steven BuechlerAn Accelerated Progression Relapse Test (APRT) and method is provided for use in the prognosis of a patient having an ER+ breast cancer. The APRT provides a determination of when a patient in a particular diseased state is likely to benefit from further disease treatment, or does not have a high probability of benefit with additional treatment. Four genetic probes are disclosed that target the MKI67, CDC6 and SPAG5 gene and gene products. The ER+ breast cancer patient population is stratified into two groups, with the low gene expression group identifying the patient/patient group that is less likely to benefit from additional treatment measures, and a high gene expression group identifying the patient group that is more likely to benefit from additional treatment measures.
History
Patent Number
US 9721067 B2Other Application
42227604Inventor
Steven BuechlerInventor from Local Institution
Steven BuechlerAssignee
University of Notre Dame du LacDate Modified
2017-11-30Language
- English
Claims
13Prior Publication Number
US 20160378934 A9 US 20150126478 A1Publisher
U.S. Patent and Trademark OfficeCooperative Patent Classification Codes
C12Q 1/6886 (20130101); G01N 33/57415 (20130101); G06F 19/20 (20130101); G06F 19/345 (20130101); C12Q 2600/106 (20130101); C12Q 2600/158 (20130101); G01N 2800/56 (20130101); G06F 19/24 (20130101); G01N 2800/52 (20130101)Contributor
Steven BuechlerInternational Patent Classification Codes
G01N 33/53 (20060101); C12Q 1/68 (20060101); G06F 19/00 (20110101); G01N 33/574 (20060101); G06F 19/20 (20110101); G06F 19/24 (20110101)Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC